Literature DB >> 25124970

The role of surfactant and non-invasive mechanical ventilation in early management of respiratory distress syndrome in premature infants.

Narayan Prabhu Iyer1, Maroun Jean Mhanna.   

Abstract

BACKGROUND: Surfactant replacement therapy has been used for few decades for the treatment of respiratory distress syndrome (RDS) and has significantly improved morbidity and mortality in premature infants. Non-invasive respiratory support has recently emerged as a strategy in the early management of RDS. In this review, we discuss the different strategies of early management of RDS. DATA SOURCES: A literature search of PubMed database was conducted to review the subject. The quality of evidence of key clinical studies was graded according to a modified grading system of the international GRADE group.
RESULTS: Continuous positive airway pressure (CPAP) with selective surfactant is a safe alternative to routine intubation, surfactant and mechanical ventilation in preterm infants with spontaneous breathing, and such an approach has been associated with decreased risk of death and bronchopulmonary dysplasia. There is a risk of pneumothorax when using a high pressure of CPAP (≥8 cm of H2O), a high partial pressure of carbon dioxide (PCO2 >75 mm of Hg), and a high fraction of inspired oxygen (FiO2 >0.6) as a threshold for intubation while on CPAP.
CONCLUSION: Not all preterm infants need surfactant treatment, and non-invasive respiratory support is a safe and effective approach.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25124970     DOI: 10.1007/s12519-014-0494-9

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  59 in total

1.  Comparing the effects of nasal synchronized intermittent positive pressure ventilation (nSIPPV) and nasal continuous positive airway pressure (nCPAP) after extubation in very low birth weight infants.

Authors:  C Moretti; C Gizzi; P Papoff; S Lampariello; M Capoferri; G Calcagnini; G Bucci
Journal:  Early Hum Dev       Date:  1999-12       Impact factor: 2.079

2.  Repeat surfactant therapy for postsurfactant slump.

Authors:  L A Katz; J M Klein
Journal:  J Perinatol       Date:  2006-05-18       Impact factor: 2.521

Review 3.  Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis.

Authors:  Hendrik S Fischer; Christoph Bührer
Journal:  Pediatrics       Date:  2013-10-21       Impact factor: 7.124

Review 4.  Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis.

Authors:  Neetu Singh; Kristy L Hawley; Kristin Viswanathan
Journal:  Pediatrics       Date:  2011-11-28       Impact factor: 7.124

5.  Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial).

Authors:  H L Halliday; W O Tarnow-Mordi; J D Corcoran; C C Patterson
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

6.  High-flow nasal cannulae in very preterm infants after extubation.

Authors:  Brett J Manley; Louise S Owen; Lex W Doyle; Chad C Andersen; David W Cartwright; Margo A Pritchard; Susan M Donath; Peter G Davis
Journal:  N Engl J Med       Date:  2013-10-10       Impact factor: 91.245

7.  Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial.

Authors:  Mario Augusto Rojas; Juan Manuel Lozano; Maria Ximena Rojas; Matthew Laughon; Carl Lewis Bose; Martin Alonso Rondon; Laura Charry; Jaime Alberto Bastidas; Luis Alfonso Perez; Catherine Rojas; Oscar Ovalle; Luz Astrid Celis; Jorge Garcia-Harker; Martha Lucia Jaramillo
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

Review 8.  Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants.

Authors:  P G Davis; D J Henderson-Smart
Journal:  Cochrane Database Syst Rev       Date:  2003

9.  Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.

Authors:  C P Speer; O Gefeller; P Groneck; E Laufkötter; C Roll; L Hanssler; K Harms; E Herting; H Boenisch; J Windeler
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-01       Impact factor: 5.747

Review 10.  Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates.

Authors:  A G De Paoli; P G Davis; B Faber; C J Morley
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  5 in total

Review 1.  Economic assessment of neonatal intensive care.

Authors:  Irene Guat Sim Cheah
Journal:  Transl Pediatr       Date:  2019-07

2.  Nasal CPAP on paediatric air transport in the Canadian Arctic: A case series.

Authors:  Holden A Sheffield; Chelsey A Sheffield
Journal:  Paediatr Child Health       Date:  2018-06-13       Impact factor: 2.253

3.  Relevance of clinical features in the prognosis of bronchopulmonary dysplasia in premature infants.

Authors:  Zhifang Du; Xiangyong Kong; Yanli Ren; Zhichun Feng; Junjin Huang; Jia Chen; Ruijuan Wang
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

4.  The therapeutic effect of mesenchymal stem cells on pulmonary myeloid cells following neonatal hyperoxic lung injury in mice.

Authors:  Ali Al-Rubaie; Andrea F Wise; Foula Sozo; Robert De Matteo; Chrishan S Samuel; Richard Harding; Sharon D Ricardo
Journal:  Respir Res       Date:  2018-06-08

5.  Surfactant Therapy for Respiratory Distress Syndrome in High- and Ultra-High-Altitude Settings.

Authors:  Xudong Duan; Jiujun Li; Long Chen; Yuan Shi; Xianyang Chen; Teng Xue; Chongde Liu; Xiaorong Wang; Quanfang Qiu; Zhen Yu; Bacuozhen Qiang; Hong Wu; Tianqi Wu; Lihong Zhang; Zhangsheng Chen; Dobje Jigme; Aili Xu; Zhuoga Mima; Zhen Da; Min Ren; Deji Gesang; Zhaxi Pubu; Chun Li; Yanchao Lv; Haoquan Zhou; Xue Zhang; Zhuoma Dawa; Wujin Gongjue; Li Wang; Li Wu; Xuelian Li
Journal:  Front Pediatr       Date:  2022-03-04       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.